JP2019515026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515026A5 JP2019515026A5 JP2019503398A JP2019503398A JP2019515026A5 JP 2019515026 A5 JP2019515026 A5 JP 2019515026A5 JP 2019503398 A JP2019503398 A JP 2019503398A JP 2019503398 A JP2019503398 A JP 2019503398A JP 2019515026 A5 JP2019515026 A5 JP 2019515026A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C**1*(C2)C2CC1 Chemical compound C**1*(C2)C2CC1 0.000 description 3
- HCOFVGDDABFNJB-UHFFFAOYSA-N CCCCc1ccccc1NCC Chemical compound CCCCc1ccccc1NCC HCOFVGDDABFNJB-UHFFFAOYSA-N 0.000 description 1
- GDGULTXZDPTNNZ-NSCUHMNNSA-N COC(/C=C/c1cc(F)c(C=O)c(F)c1)=O Chemical compound COC(/C=C/c1cc(F)c(C=O)c(F)c1)=O GDGULTXZDPTNNZ-NSCUHMNNSA-N 0.000 description 1
- RSVHQPLZYJNYJP-SVMLNYGMSA-N C[C@H](C1)N2C3(CC4C3)C4c3cc(/C=C/C(OC)=O)cc(F)c3[C@@H]2c2c1c(cccc1)c1[nH]2 Chemical compound C[C@H](C1)N2C3(CC4C3)C4c3cc(/C=C/C(OC)=O)cc(F)c3[C@@H]2c2c1c(cccc1)c1[nH]2 RSVHQPLZYJNYJP-SVMLNYGMSA-N 0.000 description 1
- BVOINHANKYWPHF-OPGSHWCFSA-N C[C@H](Cc1c[nH]c2ccccc12)NC1(C2)CC2C1 Chemical compound C[C@H](Cc1c[nH]c2ccccc12)NC1(C2)CC2C1 BVOINHANKYWPHF-OPGSHWCFSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127863A JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317254P | 2016-04-01 | 2016-04-01 | |
| US62/317,254 | 2016-04-01 | ||
| PCT/US2017/024809 WO2017172957A1 (en) | 2016-04-01 | 2017-03-29 | Estrogen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127863A Division JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515026A JP2019515026A (ja) | 2019-06-06 |
| JP2019515026A5 true JP2019515026A5 (enExample) | 2020-05-07 |
| JP6926189B2 JP6926189B2 (ja) | 2021-08-25 |
Family
ID=59966438
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503398A Active JP6926189B2 (ja) | 2016-04-01 | 2017-03-29 | エストロゲン受容体調節薬 |
| JP2021127863A Pending JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127863A Pending JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190142811A1 (enExample) |
| EP (1) | EP3442971B1 (enExample) |
| JP (2) | JP6926189B2 (enExample) |
| KR (2) | KR102401841B1 (enExample) |
| CN (4) | CN113717170A (enExample) |
| AR (1) | AR108011A1 (enExample) |
| AU (3) | AU2017242027B2 (enExample) |
| CA (1) | CA3017388C (enExample) |
| ES (1) | ES2991862T3 (enExample) |
| IL (3) | IL295050A (enExample) |
| MX (2) | MX392461B (enExample) |
| RU (1) | RU2738646C2 (enExample) |
| SG (1) | SG11201807708SA (enExample) |
| TW (2) | TWI746535B (enExample) |
| WO (1) | WO2017172957A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136688A1 (en) | 2016-02-05 | 2017-08-10 | Inventisbio Inc. | Selective estrogen receptor degraders and uses thereof |
| CA3017388C (en) * | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| CN111164063A (zh) | 2017-09-11 | 2020-05-15 | 里科瑞尔姆Ip控股有限责任公司 | 用于制备双环化合物的连续流动方法 |
| EP3709997A1 (en) * | 2017-11-16 | 2020-09-23 | Novartis AG | Pharmaceutical combination comprising lsz102 and ribociclib |
| JP7736570B2 (ja) | 2019-05-24 | 2025-09-09 | 浙江海正薬業股▲ふん▼有限公司 | アクリル酸系誘導体の結晶形およびその調製方法及び用途 |
| US11278532B2 (en) * | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
| KR20220103977A (ko) * | 2019-11-04 | 2022-07-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제의 염 및 형태 |
| CA3165382A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| WO2021127042A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| CN115023228A (zh) * | 2019-12-20 | 2022-09-06 | 里科瑞尔姆Ip控股有限责任公司 | 组合 |
| KR20220119428A (ko) * | 2019-12-20 | 2022-08-29 | 리커리엄 아이피 홀딩스, 엘엘씨 | 복합제 |
| BR112022012280A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| MX2022012828A (es) * | 2020-04-22 | 2023-01-04 | Recurium Ip Holdings Llc | Preparación de un degradador selectivo de receptores de estrógeno. |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| AU2021343525A1 (en) * | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
| WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
| JP2024502270A (ja) * | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| WO2022153268A1 (en) | 2021-01-15 | 2022-07-21 | Beckley Psytech Limited | Tryptamine analogues |
| AU2022305957A1 (en) * | 2021-07-08 | 2024-01-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ264996A3 (cs) | 1994-03-11 | 1998-01-14 | Eli Lilly And Company | Použití sloučenin, které jsou aktivní na 5HT2B receptor |
| GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| ES2278064T3 (es) | 2001-10-19 | 2007-08-01 | Transtech Pharma Inc. | Derivados de beta-carbolina como inhibidores de ptp. |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| WO2006015035A1 (en) | 2004-08-02 | 2006-02-09 | Smithkline Beecham Corporation | Useful compounds for hpv infection |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| EP2139476A1 (en) | 2007-04-13 | 2010-01-06 | PTC Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| AU2010279183B2 (en) * | 2009-07-28 | 2015-10-29 | Ono Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
| WO2011088025A1 (en) | 2010-01-15 | 2011-07-21 | Merck Sharp & Dohme Corp. | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| EP2534152B1 (en) * | 2010-02-11 | 2018-05-02 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
| US20130172320A1 (en) | 2010-02-18 | 2013-07-04 | Sarvajit Chakravarty | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| BR112012031464A2 (pt) | 2010-06-10 | 2020-08-04 | Aragon Pharmaceuticals, Inc. | moduladores do receptor de estrogênio e os seus usos |
| EP2669279B1 (en) * | 2011-01-27 | 2017-01-11 | ONO Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
| CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| RS56616B1 (sr) * | 2011-12-31 | 2018-02-28 | Beigene Ltd | Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori |
| RU2014136339A (ru) * | 2012-02-07 | 2016-03-27 | Иолас Терапьютикс, Инк. | Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов |
| EA201491530A1 (ru) | 2012-03-20 | 2015-07-30 | Серагон Фармасьютикалс, Инк. | Модуляторы рецепторов эстрогенов и их применение |
| MX375256B (es) | 2012-07-13 | 2025-03-06 | Gtx Inc | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
| EP2958907B1 (en) | 2013-02-19 | 2018-02-28 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| JP2016517420A (ja) | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ， インク． | 多環式エストロゲン受容体モジュレーター及びその使用 |
| DK3004090T3 (en) * | 2013-05-28 | 2018-01-08 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| EP3089747A1 (en) | 2013-12-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
| UY35993A (es) * | 2014-02-12 | 2015-08-31 | Eolas Therapeutics Inc | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina |
| WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| US9796686B2 (en) | 2014-05-16 | 2017-10-24 | Idorsia Pharmaceuticals Ltd | Antibacterial quinazoline-4(3H)-one derivatives |
| CN111978319B (zh) | 2014-06-27 | 2023-08-11 | 诺格拉制药有限公司 | 芳基受体调制剂及其制备和使用方法 |
| SG11201702900SA (en) | 2014-10-09 | 2017-05-30 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Hydroxyl purine compounds and applications thereof |
| RU2019115778A (ru) | 2015-04-21 | 2019-06-24 | Джи Ти Икс, ИНК. | Селективные лиганды - разрушители андрогенных рецепторов (sard) и способы их применения |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| MX372914B (es) * | 2015-06-16 | 2020-04-27 | Jiangsu Hengrui Medicine Co | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. |
| US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| WO2017136688A1 (en) * | 2016-02-05 | 2017-08-10 | Inventisbio Inc. | Selective estrogen receptor degraders and uses thereof |
| CA3017388C (en) * | 2016-04-01 | 2024-03-12 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| CA3024615A1 (en) | 2016-06-10 | 2017-12-14 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
-
2017
- 2017-03-29 CA CA3017388A patent/CA3017388C/en active Active
- 2017-03-29 KR KR1020187030841A patent/KR102401841B1/ko active Active
- 2017-03-29 SG SG11201807708SA patent/SG11201807708SA/en unknown
- 2017-03-29 JP JP2019503398A patent/JP6926189B2/ja active Active
- 2017-03-29 EP EP17776574.0A patent/EP3442971B1/en active Active
- 2017-03-29 CN CN202111035485.4A patent/CN113717170A/zh active Pending
- 2017-03-29 KR KR1020227016946A patent/KR20220071293A/ko not_active Ceased
- 2017-03-29 WO PCT/US2017/024809 patent/WO2017172957A1/en not_active Ceased
- 2017-03-29 CN CN202011582784.5A patent/CN112745316A/zh active Pending
- 2017-03-29 CN CN201780033815.1A patent/CN109311870B/zh active Active
- 2017-03-29 IL IL295050A patent/IL295050A/en unknown
- 2017-03-29 MX MX2018011419A patent/MX392461B/es unknown
- 2017-03-29 US US16/086,434 patent/US20190142811A1/en not_active Abandoned
- 2017-03-29 CN CN202011582762.9A patent/CN112679495B/zh active Active
- 2017-03-29 AU AU2017242027A patent/AU2017242027B2/en active Active
- 2017-03-29 RU RU2018132037A patent/RU2738646C2/ru active
- 2017-03-29 ES ES17776574T patent/ES2991862T3/es active Active
- 2017-03-29 IL IL285318A patent/IL285318B/en unknown
- 2017-03-30 AR ARP170100788A patent/AR108011A1/es unknown
- 2017-03-30 TW TW106110662A patent/TWI746535B/zh active
- 2017-03-30 TW TW110145253A patent/TW202235418A/zh unknown
-
2018
- 2018-09-06 IL IL261654A patent/IL261654B/en unknown
- 2018-09-24 MX MX2022005780A patent/MX2022005780A/es unknown
-
2020
- 2020-05-05 US US16/866,900 patent/US11065233B2/en active Active
- 2020-05-05 US US16/867,017 patent/US11065234B2/en active Active
- 2020-05-05 US US16/866,995 patent/US10959989B2/en active Active
- 2020-12-22 AU AU2020294196A patent/AU2020294196B2/en active Active
-
2021
- 2021-07-06 US US17/305,369 patent/US20210330651A1/en not_active Abandoned
- 2021-08-04 JP JP2021127863A patent/JP2021176911A/ja active Pending
-
2022
- 2022-06-09 AU AU2022204025A patent/AU2022204025A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515026A5 (enExample) | ||
| RU2018132037A (ru) | Модуляторы эстрогеновых рецепторов | |
| JP2012515776A5 (enExample) | ||
| JP2018138577A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP7319977B2 (ja) | チューブリン阻害剤 | |
| JP2013541536A5 (enExample) | ||
| JP2022071077A5 (enExample) | ||
| JP2013525458A5 (enExample) | ||
| JP2019077713A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| JP2013522292A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2020517611A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2017521375A5 (enExample) | ||
| JP2014502599A5 (enExample) | ||
| TWI291955B (en) | Novel indole derivatives and their use as medicaments | |
| CN114364685A (zh) | 含氮杂环类化合物，及其制备方法、药物组合物和应用 | |
| JP2012509265A5 (enExample) | ||
| JP2012515210A5 (enExample) | ||
| JP2010539155A5 (enExample) | ||
| JP2016510719A5 (enExample) | ||
| JP2014522854A5 (enExample) |